Epic Plus, Epic Plus Supra, Epic Max, Epic Elite, Epic Supra G3 Tissue Heart Valves
ABBOTT MEDICAL · Decision date Sep 18, 2026
What did the FDA decide?
FDA's decision OK30 dated 2026-09-18 covers P040021/S063, a 30-Day Notice from Abbott Medical described under the reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. The listed products are the Epic Plus, Epic Plus Supra, Epic Max, Epic Elite and Epic Supra G3 tissue heart valves, with product code LWR. The supplement number establishes a link to PMA P040021, but this action is a manufacturing supplement to that PMA, not an approval of a new device or of the whole valve system.
The reported change has two parts: removal of the destructive pinch inspection at receiving, applicable only to Epic Elite and Epic Supra G3, and addition of a non-destructive stent pinch inspection as a 100% in-process control for all Epic valves. The source does not give inspection methods, acceptance criteria, or data on safety or clinical performance, so the notice's stated purpose should not be read as independent evidence of either.
FDA approval order statement
removal of the destructive pinch inspection at receiving (applicable to Epic Elite and Epic Supra G3 only) and the addition of a new non-destructive stent pinch inspection as a 100% in-process control for all Epic valves
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 18, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P040021/S063
- Regulatory pathway
- PMA supplement
- Applicant
- ABBOTT MEDICAL
- Product code
- LWR
- Decision code
- OK30
- Decision date
- Sep 18, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: heart-valve, non-allograft tissue.
- Applicant
- Abbott Medical
- Product code
- LWR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P040021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P040021 · Original PMA
SJM BIOCOR VALVE / SJM BIOCOR SUPRA VALVE
P040021/S063 received
Application receipt date recorded by FDA.
P040021/S063 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P040021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P040021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| ABBOTT MEDICAL | PMA approval | Aug 5, 2005 | FDA |
Explore the linked device profile
Other records with product code LWR
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
EDWARDS INTUITY Elite Valve System (8300AB)P150036/S081 | Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA |
| Edwards Lifesciences, LLC | PMA supplement | Oct 28, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA supplement | Oct 22, 2026 | FDA | |
| Edwards Lifesciences, LLC | PMA approval | Jun 29, 2017 | FDA | |
| Edwards Lifesciences, LLC | PMA approval | Aug 12, 2016 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Abbott Medical
- Headquarters
- Not reported
- Brand website
- abbott.com
- FDA applicant address
- 177 County Rd. B E., St. Paul, MN, 55117
Sources and methodology
- Original FDA record: P040021/S063
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records